Principal Scientist II AbbVie Vernon Hills, Illinois
Setting up comprehensive control strategies requires advanced analytical methods and technologies for complex antibody drug conjugates (ADCs) CMC development. This presentation discusses advanced analytical methods and technologies using case studies, for accurate and complementary characterization of challenging critical quality attributes (CQAs) of ADCs such as free drug residues, antibody-to-drug ratio (DAR) and drug load distribution (DLD).
Learning Objectives:
Overall control strategies for antibody-drug conjugate (ADC) CMC development
Case studies in advanced analytical methods for technologies for CQA characterization of ADCs
